Viridian Therapeutics (VRDN) AI Stock Analysis

• Market Cap: $1.13B
• Dividend Yield: N/A
• Average Volume (3M): 919.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.65
• Revenue Growth: 4.86%
• EPS Growth: 10.13%
• Country: US
• Employees: 143
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): -0.87
• Shares Outstanding: 81,592,026
• 10 Day Avg. Volume: 826,538
• 30 Day Avg. Volume: 918,999
• PEG Ratio: -0.87
• Price to Book (P/B): 1.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $38.80
• Price Target Upside: 183.83% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12

• Rating: 51 Neutral
• Price Target: $13.50 ▼( -1.24% Downside)

Viridian Therapeutics' overall stock score is influenced primarily by its significant financial challenges and a cautious technical outlook. However, the positive phase 3 trial results and strategic board appointment provide some optimism for future growth, balancing the financial difficulties.

Positive Factors

Efficacy and Safety

Veligrotug shows comparable-to-better efficacy and safety with a less burdensome infusion regimen, making it a preferred IV option for Thyroid Eye Disease treatment.

FDA Designation

Veligrotug recently received FDA Breakthrough Therapy Designation for the treatment of Thyroid Eye Disease, supporting eligibility for Priority Review.

Negative Factors

Profitability

Viridian is not yet profitable and will likely require additional funding for development and commercialization.

Regulatory Approval

Key risks include the need for regulatory approval and competition against larger organizations like Horizon.

Viridian Therapeutics Business Overview & Revenue Model

Company Description

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Viridian Therapeutics makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model typically involves the sale of pharmaceutical products upon receiving regulatory approval and successfully launching them to the market. Additionally, Viridian may engage in strategic collaborations and partnerships with other pharmaceutical companies to co-develop therapies, which can provide milestone payments, royalties, and licensing fees as additional revenue streams. These partnerships can also enhance the company's research and development capabilities while expanding its market reach for the commercialized therapies.

Viridian Therapeutics Financial Statement Overview

Summary

Viridian Therapeutics faces significant financial challenges with no revenue generation in 2024, consistent operational inefficiencies, and negative free cash flow. Despite a strong cash position and low leverage, the sustainability risks due to ongoing losses and cash burn rate are concerning.

Income Statement

Viridian Therapeutics has struggled with revenue generation, evident from the decrease in total revenue from $4.46M in 2019 to zero in 2024, indicating significant challenges in market traction or product development. Consistently negative net income and EBIT highlight ongoing operational inefficiencies. The company also experienced declining gross and net profit margins over the years, reflecting persistent unprofitability.

Balance Sheet

The balance sheet reveals a strong cash position with cash and cash equivalents growing to $717.6M by 2024, but the absence of revenue poses a risk to long-term sustainability. The company's debt-to-equity ratio is favorable due to minimal debt, suggesting low leverage. However, a consistent decline in equity ratio from 52% in 2019 to 90% in 2024 reflects potential over-reliance on equity financing.

Cash Flow

Operating cash flow has been consistently negative, indicating that the company is not generating sufficient cash from its core operations. While there is a notable increase in financing cash flow, reflecting successful fundraising efforts, free cash flow remains negative, pointing to potential cash burn issues. The absence of revenue growth and high cash burn rate are concerning for future liquidity.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
302.00K	314.00K	1.77M	2.96M	1.05M
	Gross Profit
302.00K	-1.01M	1.02M	2.34M	-27.25M
	EBIT
-299.04M	-254.45M	-134.30M	-79.73M	-110.38M
	EBITDA
-266.36M	-234.56M	-128.63M	-78.79M	-109.67M
	Net Income Common Stockholders
-269.95M	-237.73M	-125.44M	-79.42M	-110.98M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
717.58M	477.37M	424.55M	196.97M	127.64M
	Total Assets
742.40M	490.42M	435.09M	203.71M	131.25M
	Total Debt
21.09M	21.05M	5.26M	520.00K	455.00K
	Net Debt
-78.50M	-81.78M	-150.32M	-41.78M	-45.44M
	Total Liabilities
70.76M	48.40M	40.03M	15.99M	11.22M
	Stockholders Equity
671.64M	442.02M	395.06M	187.72M	120.04M
Cash Flow		Free Cash Flow
-232.83M	-185.07M	-94.64M	-54.92M	-29.82M
	Operating Cash Flow
-232.32M	-184.17M	-93.84M	-54.58M	-29.78M
	Investing Cash Flow
-228.65M	-94.25M	-115.13M	-74.29M	-50.48M
	Financing Cash Flow
457.74M	225.67M	322.24M	125.28M	101.31M

Viridian Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.67
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRDN, the sentiment is Positive. The current price of 13.67 is above the 20-day moving average (MA) of 13.08, above the 50-day MA of 13.43, and below the 200-day MA of 17.85, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 54.79 is Neutral, neither overbought nor oversold. The STOCH value of 76.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VRDN.

Viridian Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	74 Outperform	$1.12B	29.94	11.23%	―	29.20%	―
Sector *	53 Neutral	$5.14B	3.06	-43.57%	2.81%	16.81%	-0.12%
VRDN	51 Neutral	$1.13B	―	-49.41%	―	4.86%	10.13%
SNDX	48 Neutral	$909.52M	―	-93.70%	―	―	-25.83%
WVE	47 Neutral	$938.68M	―	-105.50%	―	-7.06%	-57.17%
GERN	42 Neutral	$885.32M	―	-45.35%	―	22264.23%	39.09%
IOVA	39 Underperform	$637.81M	―	-51.85%	―	11070.12%	32.07%

Viridian Therapeutics Corporate Events

Viridian Reports Positive Phase 3 Trial Results

On May 20, 2025, Viridian Therapeutics announced positive long-term durability data from its THRIVE phase 3 clinical trial for veligrotug, an anti-IGF-1R antibody for thyroid eye disease (TED). The trial showed that 70% of patients maintained their response at week 52, with no changes in safety profile. Veligrotug has received Breakthrough Therapy Designation, and the company plans a Biologics License Application submission in the second half of 2025, with a commercial launch anticipated in 2026.

The most recent analyst rating on (VRDN) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.

Viridian Therapeutics Appoints Jeff Ajer to Board

On April 7, 2025, Viridian Therapeutics announced the appointment of Jeff Ajer to its Board of Directors. Mr. Ajer brings over 25 years of experience in commercialization for rare diseases, having previously served as Chief Commercial Officer at BioMarin Pharmaceutical. His expertise is expected to bolster Viridian’s commercial strategy as the company advances its pipeline, including veligrotug for thyroid eye disease. Additionally, Viridian announced inducement grants of stock options to new employees, aligning with its growth and recruitment strategies.

Viridian Therapeutics Enters New $300M Sale Agreement

On March 3, 2025, Viridian Therapeutics entered into a new Open Market Sale Agreement with Jefferies LLC, allowing the company to offer and sell up to $300 million in common stock to support clinical development and commercialization efforts. This new agreement replaces a prior sale agreement from September 2022, which was terminated after selling $115.2 million in stock, with no costs associated with its early termination.